In a report issued on March 11, Ross L Smotrich from Barclays maintained a Buy rating on Cellectis SA (CLLS), with a price target of $50. The company’s shares closed yesterday at $18.71, close to its 52-week low of $15.34.
According to TipRanks.com, Smotrich is a 5-star analyst with an average return of 7.2% and a 67.0% success rate. Smotrich covers the Financial sector, focusing on stocks such as Essential Properties Realty Trust Inc, Pennsylvania Real Estate Investment, and Apartment Investment & Management.
Cellectis SA has an analyst consensus of Moderate Buy, with a price target consensus of $35.25, an 88.4% upside from current levels. In a report released yesterday, Oppenheimer also assigned a Buy rating to the stock with a $44 price target.
See today’s analyst top recommended stocks >>
Based on Cellectis SA’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $22.84 million. In comparison, last year the company had a GAAP net loss of $28.51 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Cellectis SA is a biopharmaceutical company, which engages in the research and development of genome engineering technology. The company operates through the following business segments: Therapeutics and Plants.
